Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-29
2006-08-29
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S081000
Reexamination Certificate
active
07098216
ABSTRACT:
The invention provides derivatives of thiazolo[4,5-d1]pyrimidine and their use as inhibitors of proinflammatory cytokines.
REFERENCES:
patent: 3127402 (1964-03-01), Pachter et al.
patent: 3594378 (1971-07-01), Laliberte et al.
patent: 3919201 (1975-11-01), Evans
patent: 4041167 (1977-08-01), Moser et al.
patent: 4091219 (1978-05-01), Denzel et al.
patent: 4103016 (1978-07-01), Moser et al.
patent: 4110451 (1978-08-01), Moser et al.
patent: 4111693 (1978-09-01), Wright et al.
patent: 4160768 (1979-07-01), Moser et al.
patent: 4175961 (1979-11-01), Wright et al.
patent: 4224334 (1980-09-01), Moser et al.
patent: 4510141 (1985-04-01), Heckendorn
patent: 4559157 (1985-12-01), Smith et al.
patent: 4593095 (1986-06-01), Snyder et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4665182 (1987-05-01), Nichol et al.
patent: 4701455 (1987-10-01), Nichol et al.
patent: 4766133 (1988-08-01), Fischli et al.
patent: 4769377 (1988-09-01), Snyder et al.
patent: 4778806 (1988-10-01), Bender et al.
patent: 4794114 (1988-12-01), Bender et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4931437 (1990-06-01), Fedi et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 4996208 (1991-02-01), Lindner et al.
patent: 5198547 (1993-03-01), Bailey et al.
patent: 5288721 (1994-02-01), Klein et al.
patent: 5294612 (1994-03-01), Bacon et al.
patent: 5317019 (1994-05-01), Bender et al.
patent: 5366978 (1994-11-01), Furukawa et al.
patent: 5424311 (1995-06-01), Billhardt-Troughton et al.
patent: 5521181 (1996-05-01), Meyer et al.
patent: 5593992 (1997-01-01), Adams et al.
patent: 5599813 (1997-02-01), Matsumoto et al.
patent: 5656644 (1997-08-01), Adams et al.
patent: 5658903 (1997-08-01), Adams et al.
patent: 5670506 (1997-09-01), Leigh et al.
patent: 5750575 (1998-05-01), Klein et al.
patent: 5792767 (1998-08-01), Meyer et al.
patent: 5843943 (1998-12-01), Carson et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 2004/0038994 (2004-02-01), Wilson
patent: 2005/0130974 (2005-06-01), Ramesh et al.
patent: 2038922 (1971-03-01), None
patent: 0188150 (1986-07-01), None
patent: 0348746 (1990-01-01), None
patent: 0490181 (1992-06-01), None
patent: 0493682 (1992-07-01), None
patent: 0733633 (1996-09-01), None
patent: 0849256 (1998-06-01), None
patent: 08-092250 (1996-04-01), None
patent: WO-92/10190 (1992-06-01), None
patent: WO-92/21344 (1992-12-01), None
patent: WO-93/06090 (1993-04-01), None
patent: WO-93/16699 (1993-09-01), None
patent: WO-96/20710 (1996-07-01), None
patent: WO-96/40143 (1996-12-01), None
patent: WO-97/25045 (1997-07-01), None
patent: WO-97/25047 (1997-07-01), None
patent: WO-97/25048 (1997-07-01), None
patent: WO-98/22464 (1998-05-01), None
patent: WO-98/52948 (1998-11-01), None
Novel Drug Delivery Systems, Second Edition, Chien, Y.W., (ed.), Marcel Dekker, Inc., New York,(1992), 197-228.
Remington's Pharmaceutical Sciences, Eighteenth Edition, Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),p. 391.
Remington's Pharmaceutical Sciences, Eighteenth Edition, Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),pp. 1115-1121.
Abdel-Fattah, A. M., et al., “Reactions with 6-Methyl-2-Thiouracil Synthesis of Dipyrimidino(2,1-b:1′,2′-c)Thiazine. A New Ring System”,Phosphorus, Sulfur, and Silicon, 72, (1992), 145-156.
Badger, A. M., et al., “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function”,The Journal of Pharmacology and Experimental Therapeutics, 279, (1996), 1453-1461.
Baker, J. A., et al., “Synthesis of Derivatives of Thizolo[4,5-d]pyrimidine. Part II”,Journal of the Chemical Society(C), 18, (1970),2478-2484.
Basyouni, W. M., et al., “Synthesis and Molluscicidal Properties of Some Newer Thiazoles and Their Thiazolo (5,4,-d) Pyrimidinone Derivatives”,Egypt. J. Bilh., 17, (1995),pp. 91-102.
Bauer, Ludwig, et al., “Thiazolo-N-hydroxyuracils”,J. Heterocycl. Che., 5(3), (1968),331-335.
Boehm, J. C., et al., “1-Substituted 4-Aryl-5-pyridinylimidazoles: A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency”,Journal of Medical Chemistry, 39(20), (Sep. 27, 1996),3929-3937.
Boujrad, N. , et al., “Inhibition of Hormone-Stimulated Steroidogenesis in Cultured Leydig Tumor Cells by a Cholesterol-Linked Phosphorothioate Oligodeoxynucleotide Antisense to Diazepam-Binding Inhibitor”,Proceedings of the National Academy of Sciences USA, 90(12), (Jun. 1993),5728-5731.
Bruns, R. F., “Adenosine Antagonism by Purines, Pteridines and Benzopteridines in Human Fibroblasts”,Biochemical Pharmacology, 30, (1981),pp. 325-333.
Burrows, J. L., “Determination of Oxpentifylline and Three Metabolites in Plasma by Automated Capillary Gas Chromatography using Nitrogen-Selective Detection”,Journal of Chromatography, 423, (1987),139-146.
Chembrzynska-Nowak, M. , et al., “Elevated Release of Tumor Necrosis Factor-alpha and Interferon-gamma by Bronchoalveolar Leukocytes from Patients with Bronchial Asthma”,American Review of Respiratory Diseases, 147, (1993),291-295.
Chaby, R. , “Strategies for the Control of LPS-Mediated Pathophysiological Disorders”,Drug Discovery Today, 4, (May 1999),209-221.
Chang, S. F., et al., “Nasal Drug Delivery”,In: Treatise on Controlled Drug Delivery, Kydonieus, A., (ed.), Marcel Dekker, Inc., New York,(1992),423-463.
Chaudhri, G. , et al., “Reactive Oxygen Species Facilitate in vitro and in vivo Lipopolysaccharide-Induced Release of Tumor Necrosis Factor”,The Journal of Immunology, 143, (Aug. 15, 1989),1290-1294.
Cifone, M. G., et al., “Apoptotic Signaling through CD95 (Fas/Apo-1) Activates an Acidic Sphingomyelinase”,The Journal of Experimental Medicine, 177, (Oct. 1993),1547-1552.
Cottam, Howard B., “New Adenosine Kinase Inhibitors with Oral Antiinflammatory Activity”,Drugs of The Future, 19 (5), (1994),pp. 485-491.
Cottam, Howard B., et al., “New Adenosine Kinase Inhibitors with Oral Antiinflammatory Activity: Synthesis and Biological Evaluation”,Journal of Medicinal Chemistry, 36 (22), (Oct. 29, 1993),pp. 3424-3430.
Cottam, H. B., et al., “Substituted Xanthines, Pteridinediones, and Related Compounds as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor alpha”,Journal of Medicinal Chemistry, 39, (1996),2-9.
Coughlan, A. F., et al., “P-Selectin and Platelet-activating Factor Mediate Initial Endotoxin-induced Neutropenia”,The Journal of Experimental Medicine, 179, (Jan. 1994),329-334.
Crouch, S. P., et al., “Effect of Ingested Pentoxifylline on Neutrophil Superoxide Anion Production”,Infection and Immunity, 60, (Nov. 1992),4504-4509.
Curran, W. V., et al., “Pteridine Chemistry. VII. The Cyanoethylation of Some Hydroxypteridines”,Chemical Abstracts, 57, As Reported by Smith, M.E.,(1962),5920-5922.
Day, C. P., et al., “Plasma Membrane Form of Phosphatidate Phosphohydrolase: a Possible Role in Signal Transduction During Liver Fibrogenesis”,Clinical Science, 85, (1993),281-287.
Dbaibo, G. S., et al., “Tumor Necrosis Factor-alpha (TNF-alpha) Signal Transduction through Ceramide”,Journal of Biological Chemistry, 268, (Aug. 25, 1993),17762-17766.
De Moraes, V. L., et al., “Effect of Cyclo-Oxygenase Inhibitors and Modulators of Cyclic AMP Formation on Lipopolysaccharide-Induced Neutrophil Infiltration in Mouse Lung”,British Journal of Pharmacology, 117, (1996),pp. 1792-1796.
Dinarello, C. A., “Interleukin-1 And Tumor Necrosis Factor: Effector Cytokines In Autoimmune Diseases”,Seminars in Immunology, 4, (1992),133-145.
Dressler, K. A., et al., “Tumor Necrosis Factor-alpha Activates the Sphingomyelin Signal Transduction Pathway in
Carson Dennis A.
Cottam Howard B.
Deng Lynn
Berch Mark L.
Schwegman Lundberg Woessner & Kluth P.A.
The Regents of the University of California
LandOfFree
Thiazolopyrimidines useful as TNFα inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazolopyrimidines useful as TNFα inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolopyrimidines useful as TNFα inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3608093